NewcelX Ltd. Adds Top Neurologist to Scientific Advisory Board
Ticker: NCEL · Form: 6-K · Filed: Nov 17, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Newcelx LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Nov 17, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: advisory-board, pharmaceuticals, personnel-appointment
TL;DR
NewcelX beefs up science board with Barrow Neurological CMO, Dr. Jeremy Shefner.
AI Summary
On November 17, 2025, NewcelX Ltd. announced the appointment of Dr. Jeremy Shefner, Chief Medical Officer at the Barrow Neurological Institute, to its Scientific Advisory Board. This move aims to bolster the company's scientific expertise as it advances its pharmaceutical development programs.
Why It Matters
The addition of a prominent medical expert like Dr. Shefner can enhance NewcelX's credibility and strategic direction in its drug development efforts, potentially attracting further investment and accelerating progress.
Risk Assessment
Risk Level: low — This filing is a routine press release announcement regarding an advisory board appointment, with no immediate financial or operational impact disclosed.
Key Players & Entities
- NewcelX Ltd. (company) — Filer of the report and subject of the press release.
- Jeremy Shefner, MD, PhD (person) — Newly appointed member of the Scientific Advisory Board.
- Barrow Neurological Institute (company) — Institution where Dr. Shefner serves as Chief Medical Officer.
- November 17, 2025 (date) — Date of the press release announcement.
FAQ
Who is Jeremy Shefner, and what is his role at the Barrow Neurological Institute?
Jeremy Shefner, MD, PhD, is the Chief Medical Officer at the Barrow Neurological Institute.
What is the significance of Dr. Shefner's appointment to NewcelX Ltd.'s Scientific Advisory Board?
His appointment is intended to strengthen NewcelX's scientific expertise and support its pharmaceutical development programs.
When was this announcement made by NewcelX Ltd.?
The announcement was made via a press release on November 17, 2025.
What type of filing is this report?
This is a Form 6-K, a report of a foreign private issuer.
What was NewcelX Ltd. formerly known as?
NewcelX Ltd. was formerly known as NLS Pharmaceutics Ltd., with a name change date of July 19, 2019.
Filing Stats: 224 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2025-11-17 07:06:35
Filing Documents
- ea0265974-6k_newcelx.htm (6-K) — 11KB
- ea026597401ex99-1_newcelx.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 28KB
- 0001213900-25-111253.txt ( ) — 60KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NewcelX Ltd. Date: November 17, 2025 By: /s/ Ronen Twito Name: Ronen Twito Title: Chief Executive Officer 3